Vaccines. There are 10 categories of patients who will be able to receive a third 'additional' dose of the anti-Covid vaccine: solid organ transplant recipients undergoing immunosuppressive therapy; hematopoietic stem cell transplant; awaiting organ transplant; T-cell therapies; oncological pathology; primary immunodeficiencies; secondary immunodeficiencies; dialysis and severe chronic renal failure; previous splenectomy; AIDS.
This is established by the circular from the Ministry of Health. Any of the 2 authorized mRNA vaccines can be used as an additional dose: Pfizer in subjects aged ≥ 12 years and Moderna in subjects aged ≥ 18. –
In particular, the following conditions are included for the additional dose, which, the circular specifies, may be updated on the basis of available evidence: solid organ transplant under immunosuppressive therapy; haematopoietic stem cell transplant (within 2 years of transplant or under immunosuppressive therapy for chronic graft-versus-host disease); waiting for organ transplant; therapies based on T cells expressing a Chimeric Antigen Receptor (CART cells); oncological or onco-haematological pathology under treatment with immunosuppressive, myelosuppressive drugs or less than 6 months after suspension of treatment; primary immunodeficiencies (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome, common variable immunodeficiency, etc.); immunodeficiencies secondary to pharmacological treatment (e.g. prolonged high-dose corticosteroid therapy, immunosuppressive drugs, biological drugs with a significant impact on the functionality of the immune system, etc.); dialysis and severe chronic renal failure; previous splenectomy; acquired immunodeficiency syndrome (AIDS) with CD4+ T-cell count < 200 cells/μL or based on clinical judgment.
Based on the indications provided previously, these subjects should have already received two doses of mRNA vaccine; however, regardless of the vaccine used for the primary cycle (Comirnaty, Spikevax, Vaxzevria, Janssen), considering the indications provided by the AIFA technical-scientific commission, the circular underlines, "it will be possible to use as an additional dose any of the two mRNA vaccines authorized in Italy: Comirnaty by BioNTech/Pfizer in subjects aged ≥ 12 years and Spikevax by Moderna in subjects aged ≥ 18 years. The additional dose must be administered at least 28 days after the last dose".
Article published on 14 September 2021 - 20:25
Video Chronicles
